Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2016

Schrock Alexa B, Frampton Garrett M, Suh James, Chalmers Zachary R, Rosenzweig Mark, Erlich Rachel L, Halmos Balazs, Goldman Jonathan, Forde Patrick, Leuenberger Kurt, Peled Nir, Kalemkerian Gregory P, Ross Jeffrey S, Stephens Philip J, Miller Vincent A, Ali Siraj M, Ou Sai-Hong Ignatius

Abstract excerpt

BACKGROUND: The hepatocyte growth factor receptor gene (MET) exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition factor (MET) tyrosine kinase inhibitors (TKIs). METHODS: Well-validated hybrid capture-based comprehensive genomic profiling was performed at the request of individual treating physicians. RESULTS: Of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CDK4 gene

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins c-met

Share to Smoking

Source

Identifiers

PMID: 27343443
DOI: 10.1016/j.jtho.2016.06.004

Genes

MET
CDK4
EGFR
KRAS
MDM2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.PMID 27343443Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.Semantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Semantic proximity Read ↗

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective.Semantic proximity Read ↗

Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.Semantic proximity Read ↗

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.Semantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.Semantic proximity Read ↗

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.